Last Updated 18 December 2015
The HIV therapy market is very dynamic. Over the last decade, many effective antiretroviral (ARV) therapies have been introduced, prompting changes in treatment guidelines and clinical practices. In particular, highly effective and safe agents called integrase strand transfer inhibitors (InSTIs) recently launched for HIV and have quickly become the standard of care for treatment-naive patients, displacing the well-entrenched single-tablet regimen (STR) Atripla. Over the next ten years, the HIV market will grow as a result of continued uptake of premium-priced STRs, including ViiV’s Triumeq (dolutegravir/abacavir/lamivudine) and Gilead’s Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]), despite the current and future availability of generic formulations of individual regimen components. Furthermore, the suite of TAF-containing regimens will drive market growth as physicians turn to these regimens rather than the less-safe TDF-based therapies.